Medizym® Tg Rem

The protein thyroglobulin (Tg) is the basic material for the synthesis of the thyroid hormones thyroxine and triiodothyronine. Thyroglobulin is only formed by the follicle cells of the thyroid gland. Healthy people show a very low concentration in the serum. Increased levels appear in inflammatory processes of the thyroid gland and in tumors.

The determination of Tg gains particular significance in the aftercare of patients whose thyroid gland was removed during the course of a tumor therapy. Without active thyroid tissue there is no Tg detectable in the serum of these patients. Already minor increase of Tg can be used as a marker for lingering or newly developing tumors.

The Medizym® Tg Rem is a highly sensitive enzyme immunoassay for the quantitative determination of thyroglobulin in the serum used in the aftercare of tumor patients after excision of the thyroid gland.

The assay is an enzyme immunoassay of the “sandwich type”, based on two monoclonal antibodies against Tg. One antibody is immobilized on the solid phase and binds Tg from the sample. The second antibody is labelled with horseradish peroxidase (HRP) and detects the bound Tg in a subsequent color reaction. The determination of Tg in patient serum can be disturbed by the presence of antibodies, therefore a recovery sample should be carried out (spiking the patient serum with a known amount of Tg).


Aftercare of thyroid carcinoma


Human thyroglobulin

Assay principle

Enzyme immunoassay


Tetramethylbenzidine (TMB), 450 nm


undiluted patient sample

Incubation time

150 min - 15 h (o/n) - 15 min, RT


quantitative [ng/ml]

Assay sensitivity

0.03 ng/ml

Assay size

96 determinations 

The Medizym®  Tg Rem contains 96 determinations. This is sufficient for the determination of the Tg content in 24 patient samples in duplicate using a recovery sample. Using the highly sensitive Medizym® Tg Rem (functional assay sensitivity 0.03 ng Tg/ml) a reoccurrence of a tumor can be detected several weeks prior to a conventional test. This clearly reduces future medical costs.

Giovanella, L., Clark, P.M., Chiovato, L.,Duntas, L., Elisei, R., Feldt-Rasmussen, U., Leenhardt, L., Luster, M., Schalin-Jäntti, C., Schott, M., Seregni, E., Rimmele, H., Smit, J. & Verburg, F.A. DIAGNOSIS OF ENDOCRINE DISEASE: Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper. Eur J Endocrinol 2014; 171(2): R33-R46.


Zöphel, K., Wunderlich, G. & Smith, B.R. Serum thyroglobulin measurements with a high sensitivity enzyme-linked immunosorbent assay: Is there a clinical benefit in patients with differentiated thyroid carcinoma? Thyroid 2003; 861-865.